Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality

The risk of premature death is high among patients on haemodialysis (HD patients). We previously determined that immunoglobulin (Ig)M antibodies against phosphorylcholine (anti‐PC) are negatively associated with increased risk of cardiovascular disease (CVD), atherosclerosis, some autoimmune diseases and mortality among HD patients in this cohort. Here, we also study other subclasses and isotypes of anti‐PC in HD patients in relation to mortality, inflammation and gender. The study group is a cohort of 209 prevalent HD patients [median age = 66 years, interquartile range (IQR) = 51–74], vintage time = 29 months (IQR = 15–58; 56% men) with a mean follow‐up period of 41 months (IQR = 20–60). Fifty‐six per cent were men. We also divided patients into inflamed C‐reactive protein (CRP) > 5·6 mg/ml and non‐inflamed CRP. Antibody levels were determined by in‐house enzyme‐linked immunosorbent assay. IgG1 anti‐PC below median was significantly associated with increased all‐cause mortality (after adjustment for confounders: P = 0·02), while IgG, IgA and IgG2 anti‐PC were not associated with this outcome. Among non‐inflamed patients, IgM and IgG1 anti‐PC were significantly associated with mortality (P = 0·047 and 0·02). IgG1 anti‐PC was significantly associated with mortality among men (P = 0·03) and trending among women (P = 0·26). IgM (as previously reported) and IgG1 anti‐PC are negatively associated with survival among HD patients and non‐inflamed HD patients, but among inflamed patients there were no associations. IgG, IgA or IgG2 anti‐PC were not associated with survival in these groups and subgroups. Further studies are needed to determine if raising anti‐PC levels, especially IgM and IgG1 anti‐PC, through immunization is beneficial.